Your browser is no longer supported. Please, upgrade your browser.
Settings
TCON TRACON Pharmaceuticals, Inc. daily Stock Chart
TCON [NASD]
TRACON Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own0.10% Shs Outstand16.91M Perf Week-14.86%
Market Cap53.27M Forward P/E- EPS next Y-1.83 Insider Trans-12.88% Shs Float14.19M Perf Month-16.00%
Income-25.90M PEG- EPS next Q-0.25 Inst Own53.50% Short Float1.88% Perf Quarter35.48%
Sales2.70M P/S19.73 EPS this Y3.10% Inst Trans10.98% Short Ratio1.85 Perf Half Y-16.00%
Book/sh1.42 P/B2.22 EPS next Y-16.60% ROA-68.30% Target Price10.10 Perf Year-49.52%
Cash/sh2.17 P/C1.45 EPS next 5Y- ROE-123.90% 52W Range2.00 - 7.30 Perf YTD-35.71%
Dividend- P/FCF- EPS past 5Y- ROI-72.80% 52W High-58.90% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low50.00% ATR0.26
Employees26 Current Ratio4.80 Sales Q/Q-50.00% Oper. Margin- RSI (14)41.15 Volatility7.95% 7.16%
OptionableNo Debt/Eq0.30 EPS Q/Q17.70% Profit Margin- Rel Volume1.33 Prev Close3.15
ShortableYes LT Debt/Eq0.29 EarningsNov 07 AMC Payout- Avg Volume144.21K Price3.00
Recom1.60 SMA20-12.98% SMA500.99% SMA200-11.40% Volume152,331 Change-4.76%
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Feb-24-15Initiated Stifel Buy $16
Feb-24-15Initiated Oppenheimer Outperform $22
Oct-15-17 09:00PM  TRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung Cancer GlobeNewswire
Oct-06-17 11:07AM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : October 6, 2017 Capital Cube
Oct-05-17 09:37AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
Sep-07-17 08:00AM  TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma GlobeNewswire +7.46%
Aug-31-17 04:05PM  TRACON Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-16-17 08:00AM  TRACON Pharmaceuticals Announces Positive Results from National Cancer Institute Phase 1/2 Trial of TRC105 and Nexavar® in Hepatocellular Cancer Published in Clinical Cancer Research GlobeNewswire
Aug-09-17 07:11PM  Edited Transcript of TCON earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
03:16PM  Tracon reports 2Q loss Associated Press
Aug-08-17 04:05PM  TRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
10:20AM  Investor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 04:05PM  TRACON to Report Second Quarter Company Highlights and Financial Results on August 8, 2017 GlobeNewswire
Jul-25-17 08:00PM  Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration GlobeNewswire
Jun-05-17 04:05PM  TRACON Pharmaceuticals Presents Positive Clinical Data from TRC105 and TRC102 Studies at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting GlobeNewswire
02:49PM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:59AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-31-17 04:05PM  TRACON Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire
May-25-17 04:05PM  TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting GlobeNewswire -6.56%
May-24-17 08:00AM  TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer GlobeNewswire
May-11-17 04:05PM  TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia GlobeNewswire
01:52PM  Edited Transcript of TCON earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 04:20PM  Tracon reports 1Q loss Associated Press
04:05PM  TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update GlobeNewswire
10:15AM  Investor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-03-17 04:05PM  TRACON to Report First Quarter Company Highlights and Financial Results on May 10, 2017 GlobeNewswire
Apr-10-17 04:05PM  TRACON Awarded Most Innovative Trial Design for Phase 3 TAPPAS Clinical Trial of TRC105 in Angiosarcoma at 2017 Clinical and Research Excellence Awards GlobeNewswire
Mar-29-17 04:05PM  TRACON Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire -8.24%
Mar-27-17 04:20PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  TRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting GlobeNewswire
Mar-21-17 11:30AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -5.49%
11:30AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-14-17 05:16PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ
04:05PM  TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC GlobeNewswire
02:59PM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:59PM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-07-17 01:04PM  TRACON PHARMACEUTICALS, INC. Financials
Mar-06-17 04:05PM  TRACON Pharmaceuticals to Present at the 29th Annual Roth Conference GlobeNewswire
Mar-01-17 03:08PM  Edited Transcript of TCON earnings conference call or presentation 28-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
06:23AM  TRACON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Feb-28-17 08:00PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
05:11PM  Tracon reports 4Q loss Associated Press
04:30PM  TRACON Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:05PM  TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2016 TRACON Pharmaceuticals Inc Earnings Release - After Market Close
Feb-21-17 04:05PM  TRACON to Report Fourth Quarter and Full Year 2016 Company Highlights and Financial Results on February 28, 2017 GlobeNewswire
Feb-16-17 08:00AM  TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma GlobeNewswire
Feb-13-17 09:47AM  Tracon Pharma Tanks on Brain Cancer Drug Failure at Investopedia
Feb-10-17 06:12AM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -14.43%
Feb-09-17 04:05PM  TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma GlobeNewswire
Feb-06-17 06:05AM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -5.05%
Jan-31-17 04:06PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin
Jan-09-17 06:05AM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
Jan-03-17 05:04PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +8.16%
11:10AM  Tuesdays Biggest Biotech and Pharma Moves
08:00AM  TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma GlobeNewswire
Dec-22-16 02:11PM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 22, 2016 +7.29%
Dec-21-16 06:54AM  Coverage initiated on Tracon Pharmaceuticals by Jefferies
06:04AM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
Dec-13-16 05:11PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
Dec-09-16 02:05PM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 9, 2016
Nov-29-16 04:05PM  TRACON Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Nov-23-16 04:07PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -12.41%
08:54AM  TRACON Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-22-16 07:05PM  TRACON Pharmaceuticals to Host Key Opinion Leader Luncheon for Investors Focused on Angiosarcoma and Prostate Cancer on December 1 in New York City GlobeNewswire
04:01PM  TRACON Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-14-16 04:12PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +20.00%
Nov-13-16 08:00AM  TRACON Pharmaceuticals Presents Clinical and Preclinical Data from Models of NASH and Liver Fibrosis at the 2016 AASLD Annual Meeting GlobeNewswire
Nov-11-16 06:00AM  TRACON Pharmaceuticals Announces Presentation of Updated Data from Phase 1b/2 Study of TRC105 and Votrient® in Patients with Angiosarcoma GlobeNewswire -11.50%
Nov-10-16 11:18AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
Nov-09-16 03:24PM  Edited Transcript of TCON earnings conference call or presentation 8-Nov-16 9:30pm GMT
06:07AM  TRACON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 04:54PM  Tracon reports 3Q loss
04:30PM  TRACON Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:17PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  TRACON Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q3 2016 TRACON Pharmaceuticals Inc Earnings Release - After Market Close
Nov-07-16 04:05PM  TRACON Pharmaceuticals to Present at Upcoming Investment Conferences GlobeNewswire
Nov-03-16 04:05PM  TRACON Pharmaceuticals Announces Clinical Data Presentation at Upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting GlobeNewswire
Nov-01-16 04:05PM  TRACON to Report Third Quarter 2016 Company Highlights and Financial Results on November 8, 2016 GlobeNewswire
Oct-20-16 04:05PM  TRACON Pharmaceuticals Reports Granting of Inducement Awards GlobeNewswire
Oct-09-16 10:00AM  TRACON Pharmaceuticals Presents Final Updated Phase 1b Results for TRC105 in Combination with Inlyta® in Renal Cell Carcinoma at the ESMO 2016 Congress GlobeNewswire
Oct-05-16 04:34PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-03-16 08:00AM  TRACON Pharmaceuticals Announces Successful Meetings with FDA and EMA for TRC105 (carotuximab) in Angiosarcoma GlobeNewswire
Sep-28-16 04:37PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ
08:00AM  TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation JJDC, Inc. GlobeNewswire
Aug-31-16 04:05PM  TRACON Pharmaceuticals to Present at Upcoming Investment Conferences GlobeNewswire
Aug-21-16 10:40AM  9 Fresh Analyst Stocks Under $10 With Massive Upside Targets at 24/7 Wall St.
Aug-15-16 01:55PM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
Aug-11-16 12:05PM  Edited Transcript of TCON earnings conference call or presentation 10-Aug-16 8:30pm GMT
06:08AM  TRACON PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Aug-10-16 04:30PM  TRACON Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:17PM  Tracon reports 2Q loss
04:14PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  TRACON Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q2 2016 TRACON Pharmaceuticals Inc Earnings Release - After Market Close
Aug-05-16 03:13PM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : August 5, 2016
Aug-03-16 04:05PM  TRACON to Report Second Quarter 2016 Company Highlights and Financial Results on August 10, 2016 GlobeNewswire
Jul-29-16 04:03PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-07-16 07:01AM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -5.80%
Jun-06-16 08:00AM  TRACON Pharmaceuticals Announces Positive Results from TRC105 and TRC102 Clinical Trials at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting GlobeNewswire
Jun-03-16 04:03PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +8.32%
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LARUE WILLIAM RDirectorJun 02Sale2.692,5006,73313,388Jun 05 07:03 PM
BARRETT M JAMES10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 06:03 PM
BARRIS PETER J10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 06:02 PM
BASKETT FOREST10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 06:01 PM
Florence Anthony A. Jr.10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 06:00 PM
KERINS PATRICK J10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 05:59 PM
KOLLURI KRISHNA KITTU10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 05:58 PM
MOTT DAVID M10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 05:57 PM
SANDELL SCOTT D10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 05:56 PM
Viswanathan Ravi10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 05:53 PM
Sonsini Peter W.10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 05:54 PM
New Enterprise Associates 14, 10% OwnerNov 29Buy5.75869,5654,999,9992,758,039Nov 29 05:49 PM